RELIABILITY OF DSMIII-R & ICD-10 SUBSTANCE USE DISORDERS

拟议的研究将确定和的评分者之间的可靠性 DSM-III-R与ICD-10精神分裂症的诊断一致性 物质使用障碍通过个人访谈使用 世卫组织/ADAMHA综合国际诊断访谈材料 滥用模块(CIDI-AM)。申请人进行的试验性研究 发现大多数DSM-III-R物质使用的一致性良好到极好 精神错乱。在拟议的研究中，对125名临床和 社区药物滥用者将接受面谈并进行测试重新测试 每名受试者设计两次访谈。在第二次面试之后 面谈以确定信息不一致的原因。 该分析将评估DSM-III-R评分员之间的可靠性，以及 ICD-10精神活性物质障碍。这两个系统将是 关于依赖综合征和危险使用的比较 和虐待。依赖标准的关键指标，如丧失 控制、渴望、突出和缩小曲目将是 检查过了。Kappa统计和95%可信区间将是 对所有比较进行计算。预计这些调查结果 这项研究将影响未来关于 药物滥用和依赖的诊断标准。 *精神活性物质包括酒精、苯丙胺、大麻、 可卡因、迷幻剂、吸入剂、阿片类药物、五氯苯酚和镇静剂， 催眠药，抗焦虑药。

The proposed study will determine the interrater reliability of and diagnostic agreements between DSM-III-R and ICD-10 psychoactive substance use disorders through personal interviews using the WHO/ADAMHA Composite International Diagnostic Interview Substance Abuse Module (CIDI-AM). A pilot study conducted by the applicant found good to excellent agreement for most DSM-III-R substance use disorders. In the proposed study a sample of 125 clinical and community substance abusers will be interviewed with a test re-test design of two interviews per subject. After the second interview the interviews to determine the reason for discrepant information. The analysis will evaluate interrater reliability of DSM-III-R, and ICD-10 psychoactive substance disorders. The two systems will be compared with respect to the dependence syndrome and hazardous use and abuse. Key indicators of dependence criteria such as loss of control, craving, salience and narrowing of repertoire will be examined. Kappa statistics and 95% confidence intervals will be calculated for all comparisons. It is expected that the findings from this study will influence future decisions about the diagnostic criteria for substance abuse and dependence. * psychoactive substances include alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, PCP, and sedatives, hypnotics,anxiolytics.